- In preclinical animal trials, it has successfully prevented the development of influenza in 100% of cases following infection with the influenza virus.
- The treatment, called SV B – I therapy, was developed using the Smart Delivery of Nutrients Technology (SDN) platform, created by renowned researcher María José Alonso.
Madrid, March 11, 2025 – The Galician biotechnology company Smart Vitamins, a spin-off of the University of Santiago de Compostela, based at the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), has raised 2.1 million euros to finance the first clinical trial of its SV B – I therapy, which, in preclinical experiments with rodents, has managed to prevent the development of the flu in 100% of cases after being infected with the Influenza virus.
This therapy has been developed using the Smart Delivery of Nutrients Technology (SDN) platform, created by the laboratory of María José Alonso, scientific director and co-founder of Smart Vitamins and a pioneer in the field of nanomedicine. This platform allows for the precise administration and distribution of drugs, vitamins, and other essential nutrients, achieving therapeutic effects through various routes of administration, one of the main ones being the topical route.
“This highly versatile technological platform, protected by a family of internationally recognized patents, has applications in the pharmaceutical, nutraceutical, and cosmetic markets, and has allowed us to create the SV B – I therapy, which has obtained very significant results in efficacy trials conducted on rodents and we hope that it will also achieve them in the clinical efficacy trial with humans, which we will begin in early 2026 in the United Kingdom,” explains Alfredo Bermúdez de Castro Franco, CEO and co-founder of Smart Vitamins.
The company, a member of the Bioga Business Technology Cluster, which has developed all the preclinical research for its flu prevention therapy with its own resources, has managed to raise 2.1 million euros for its first clinical trial through high-value strategic investors such as Vicente Durán, president of the Medpoint group; Antonio Parente, president of GP Pharm and BCN Peptides; Roberto Conde, founder of Nutrición Médica Cantabria Labs; Santiago Domínguez, partner at Sémola Ventures and president of SCiY (a division of Bruker Biospin); Mauricio Peralta, general manager of the Medpoint group; José Luis del Río, CEO of Arcano; and Roberto Pomares, managing partner of Addleshaw Goddard Spain, among others.
“We have witnessed, through more than two years of collaboration, the enormous potential of the technology developed by Smart Vitamins in the field of respiratory infections, autoimmune diseases, and ophthalmology; therefore, we wanted to participate in the company by leading its first round of financing, with the aim of achieving the commercialization of its therapy to prevent respiratory infections and advance its developments in the dermatological field,” says Vicente Durán, president of the Medpoint group.
Thanks to this funding round, Smart Vitamins will also be able to validate the effectiveness of its therapy against other respiratory viruses such as Sars Cov 2 and Respiratory Syncytial Virus, as well as expand its patent portfolio.
“With this funding round, subscribed entirely by high-value strategic investors, we have brought together all the elements of the value chain necessary to bring our SV B – I therapy to market: we have the funding needed to conduct the first clinical trial and we have the manufacturing and distribution capabilities for the therapy globally. Furthermore, this round will allow us to accelerate the market translation of our developments in the fields of clinical and cosmetic dermatology, and ophthalmology,” emphasizes the company’s CEO.
About Smart Vitamins
Smart Vitamins is a spin-off company from the University of Santiago de Compostela that has developed innovative technology for creating therapies with intelligent nano-vehicles, based on synergistic combinations of essential nutrients and/or drugs. It features “Smart Delivery of Nutrients Technology™” (SDN Technology™), an innovative technological platform developed by María José Alonso’s laboratory, which allows for the precise administration and distribution of drugs, vitamins, and other essential nutrients, achieving unprecedented therapeutic effects through various routes of administration. Furthermore, it enables the creation of innovative therapies for multiple applications, including autoimmune, inflammatory, degenerative, and infectious diseases, among others; as well as the administration of lower effective doses of these nutrients and active ingredients, reducing toxicity and, consequently, side effects. SDN Technology™ is a technological platform protected by a family of globally recognized patents, with applications in the pharmaceutical, nutraceutical, food, and cosmetic markets.
